Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease

Journal of the Neurological Sciences

Volumn 141, Issue 1-2, 1996, Pages 39-44

  Jiménez Jiménez, Félix Javier ^a,c   Molina, José Antonio ^b   Vargas, Carmela ^b   Gómez, Pilar ^b   Navarro, José Antonio ^b   Benito Leon, Julián ^b   Ortí Pareja, Miguel ^a   Gasalla, Teresa ^a   Cisneros, Elena ^b   Arenas, Joaquín ^b  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c C/ Corregidor Jose de Pasamonte   (Spain)

Author keywords

Aspartate; Cerebrospinal fluid; Glutamate; Glycine; Neurotransmitter amino acid; Parkinson's disease; Plasma

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID; ASPARAGINE; ASPARTIC ACID; GLUTAMIC ACID; GLUTAMINE; GLYCINE; NEUROTRANSMITTER;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0342759343     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-510X(96)00115-3     Document Type: Article

References (42)

1. Abbott, R.J., J. Keidan, I.F. Pye and S.R. Nahorski (1981) Effect of freezing on gamma-aminobutyric acid levels in human cerebrospinal fluid, J. Neurochem., 37: 1042-1044.
2. Abbott, R.J., I.F. Pye and S.R. Nahorski (1982) CSF and plasma GABA levels in Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 45: 253-256.
3. Adriaens, P., B. Meesschaert, W. Wuyts, H. Vanderhaeghe and H. Eyssen (1977) Separation of ninhydrin-positive compounds on a single-column amino acid analyzer using lithium buffers. J. Chromatogr., 140: 103-108.
4. Agid, Y., M. Ruberg, R. Raisman, E. Hirsch and F. Javoy-Agid (1990) The biochemistry of Parkinson's disease. In Stern, G.M., (Ed.). Parkinson's disease. Chapman and Hall Ltd., London, pp. 99-125.
5. Alexander, G.E. and M.D. Crutcher (1990) Functional architecture or basal ganglia circuits: neural substrates of parallel processing, Trends Neurosci., 13: 266-271.
6. Araki, K., T. Takino, S. Ida and K. Kuriyama (1986) Alteration of amino acids in cerebrospinal fluid from patients with Parkinson's disease and spinocerebellar degeneration. Acta Neurol. Scand., 73: 105-110.
7. Bonnet, A.M., G. Tell, P.J. Schechter, J. Grove, M.H. Saint-Hilaire, Y. De Smet and Y. Agid (1987) Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea, Mov. Disord., 2: 117-123.
8. Cooper, J.R., F.E. Bloom and R.H. Roth (1991) Amino acid transmitters. In Cooper, J.R., F.E. Bloom and R.H. Roth (Eds.) The biochemical basis of the neuropharmacology, 6th ed. Oxford University Press, New York-Oxford, pp. 133-189.
9. De Jong, P.J., J.P. Lakke and A.W. Teelken (1984) CSF GABA levels in Parkinson's disease. Adv. Neurol., 40: 427-430.
10. DeLorey, T.M. and R.W. Olsen (1994) GABA and glycine. In Siegel, G.J., B.W. Agranoff, R.W. Albers and P.B. Molinoff (Eds.) Basic Neurochemistry: molecular, cellular, and medical aspects. Vth ed. Raven Press, New York, pp. 389-399.
11. Dingledine, R. and C.J. McBain (1994) Excitatory amino acid transmitv ters. In Siegel, G.J., B.W. Agranoff, R.W. Albers and P.B. Molinoff (Eds.) Basic Neurochemistry: molecular, cellular, and medical aspects. Vth ed. Raven Press, New York, pp. 367-387.
12. Enna, S.J., L.Z. Stern, G.J. Wastek and H.I. Yamamura (1977) Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders, Arch. Neurol., 34: 683-685.
13. Fahn, S., R.L. Elton and members of the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In Fahn, S., C.D. Marsden, M. Goldstein and D.B. Calne (Eds.). Recent developv ments in Parkinson's disease, MacMillan, Florham Park, New Jersey, vo. II, pp. 153-163.
14. Ferrarese, C., N. Pecora, M. Frigo, I. Appollonio and L. Frattola (1993) Assessment of reliability and biological significance of glutamate levels in cerebrospinal fluid, Ann. Neurol., 33: 316-319.
15. Ferraro, T.N. and T.A. Hare (1985) Free and conjugated amino acids in human CSF: influence of age and sex, Brain Res., 338: 53-60.
16. Gjessing, L.R., P. Gjesdahl, P. Dietrichson and J. Presthus (1974) Free amino acids in the cerebrospinal fluid in old age and in Parkinson's disease, Eur. Neurol., 12: 33-37.
17. Gründig, E. and F. Gerstenbrand (1970) Über den Zusammenhang zwischen der Parkinson-Symptomatik und einer Storung des Aminosaurev haushaltes im ZNS, Wien. Klin. Wochenschr., 82: 811-816.
18. Hare, T.A., S. Vanna, B. Beasley, R. Chambers and W.H. Vogel (1971) Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease, J. Lab. Clin. Med., 77: 319-325.
19. Hoehn, M.M. and M.D. Yahr (1967) Parkinsonism: onset, progression, and mortality, Neurology, 17: 419-423.
20. Hughes, A.J., S.E. Ben-Shlomo, S.E. Daniel and A.J. Lees (1992) What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathological study, Neurology, 42: 1142-1146.
21. Iwasaki, Y., K. Ikeda, T. Shiojima and M. Kinoshita (1992) Increased plasma concentrations of aspartate, glutamate and glycine in Parkinv son's disease, Neurosci. Lett., 145: 175-177.
22. Kish, S.J., A. Rajput, J. Gilbert, B. Rozdilsky, L.J. Chang, K. Shannak and O. Hornykiewicz (1986) Elevated gamma-amino-butyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss, Ann. Neurol. 20: 26-31.
23. Kuroda, H (1983) Gamma-aminobutyric acid (GABA) in cerebrospinal fluid, Acta Med. Okayama, 37: 167-177.
24. Kuroda, H., N. Ogawa, Y. Yamawaki, I. Nukina, T. Ofuji, M. Yamamoto and S. Otsuki (1982) Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases, J. Neurol. Neurosurg. Psychiatry, 45: 257-260.
25. Lakke, J.P. and A.W. Teelken (1976) Amino acid abnormalities in cerebrospinal fluid of patients with parkinsonism and extrapyramidal disorders, Neurology, 26: 489-493.
26. Lakke, J.P., A.W. Teelken, H, van der Voet and B.G. Wolthers (1987) Amino acid abnormalities in cerebrospinal fluid and blood serum of patients with Parkinson's disease, other heredodegenerative disorders and head injuries, Adv. Neurol., 45: 243-247.
27. Lloyd, K.G. and O. Hornykiewicz (1973) L-glutamic acid decarboxylase in Parkinson's disease: effect of L-DOPA therapy, Nature (London), 243: 521-523.
28. Manyam, B.V. (1982) Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa, Arch. Neurol., 39: 391-392.
29. Manyam, B.V., T.N. Ferraro and T.A. Hare (1988) Cerebrospinal fluid amino compounds in Parkinson's disease. Alterations due to carbidopa/levodopa, Arch. Neurol., 45: 48-50.
30. Manyam, B.V., L. Katz, T.A. Hare, J.C. Gerber 3d. and M.H. Grossman (1980) Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders, Arch. Neurol., 37: 352-355.
31. Manyam, B.V. and R.D. Tremblay (1984) Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid, Brain Res., 307: 217-223.
32. McGeer, P.L. and E.G. McGeer (1976) Enzyme associated with the metabolism of catecholamines, acetylcholine and GABA in human controls and patients with Parkinson's disease and Huntington chorea, J. Neurochem., 26: 65-76.
33. Moreu, E., L.M. Molinero and E. Fernández (1990) R-Sigma, Base de datos bioestadística para un ordenador personal, Horus Hardware, Madrid.
34. Perry, T.L., F. Javoy-Agid, Y. Agid, Y and H.C. Fibiger (1983) Striatal GABAergic neuronal activity is not reduced in Parkinson's disease, J. Neurochem., 40: 1120-1123.
35. Perschak, H., U. Amsler, A. Vischer, J. Siegfried and M. Cuenod (1987) Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders, Hum. Neurobiol., 6: 191-194.
36. Rinne, J.O., T. Halonen, P.J. Riekkinen and U.K. Rinne (1988) Free amino acids in the brain of patients with Parkinson's disease, Neurosci. Lett., 94: 82-86.
37. Soghomonian, J.J., S. Pedneault, G. Audet and A. Parent (1994) Increased glutamate decarboxylase mRNA levels in the striatum and pallidum of MPTP-treated primates, J. Neurosci., 14: 6256-6265.
38. Teychenné, P.F., M.G. Ziegler, C.R. Lake and S.J. Enna (1982) Low CSF GABA in parkinsonian patients who respond poorly to therapy or suffer from the 'on-off' phenomenon, Ann. Neurol., 11: 76-79.
39. Tohgi, H., T. Abe, K. Hashiguchi, S. Takahashi, Y. Nozaki and T. Kikuchi (1991) A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease and spinocerebellar degeneration, Neurosci. Lett., 126: 155-158.
40. Tutscheck, R., K.D. Meier, F. Grünig and W. Stubba (1977) Amino acid analysis of physiological fluids by a single-column programme based on stepwise elution with lithium citrate, J. Chromatogr., 139: 211-214.
41. Van Sande, M., J. Caers and A. Lowenthal (1971) Cerebrospinal fluid amino acids in extrapyramidal disorders before and after L-DOPA treatment, Z. Neurol., 199: 24-29.
42. Young, A.B. and J.B. Penney (1993) Biochemical and functional organiv zation of the basal ganglia. In Jankovic, J. and E. Tolosa (Eds.). Parkinson's disease and movement disorders, 2nd ed., Williams & Wilkins, Baltimore, pp. 1-11.